Currently, there is no ideal antigen for AML-directed immunotherapy since most targets are either expressed on normal hematopoietic stem cells (e.g., CD33 or CD123) or mature neutrophils (e.g., CLL-1) (4, 23–25). The gene discussed is CD33; the disease is acute myeloid leukemia.